ASR Rulemaking Will Hinge On Risk Levels; AmpliChip Clarification Awaited
This article was originally published in The Gray Sheet
Executive Summary
Clarification on the regulation of microarrays as analyte-specific reagents likely will be provided in a letter from FDA to Roche Molecular Diagnostics within the next two weeks
You may also be interested in...
AmpliChip Microarray Could Take De Novo Premarket Route, FDA Tells Roche
Roche must submit a 510(k) application before commercializing its AmpliChip CYP450 microarray, FDA says in a letter clarifying its regulatory stance on the technology
AmpliChip Microarray Could Take De Novo Premarket Route, FDA Tells Roche
Roche must submit a 510(k) application before commercializing its AmpliChip CYP450 microarray, FDA says in a letter clarifying its regulatory stance on the technology
IVAT Proposal In Limbo As Industry Coalition Seeks Audience WIth FDA
Stakeholders are seeking clarification on agency concerns regarding industry's in vitro analytical test premarket proposal, following an Oct. 24 meeting between reps from OIVD and the IVAT industry coalition